Home > News > Exclusive proprietary Chinese medicines ignite the stomach medicine market!

Exclusive proprietary Chinese medicines ignite the stomach medicine market!

06. 13 , 2024

未命名(2)(14) (2)

Proprietary Chinese medicines to treat gastric diseases are increasingly favoured by patients, the market is getting hotter and hotter, mene.com data show that in 2023 in China's three major terminals and six markets (see the end of this article for the scope of the statistics) proprietary gastric medicine (gastritis, ulcers) combined market size of 10.4 billion yuan. In the public medical terminal, Yangzijiang two exclusive products combined sales of more than 1.1 billion yuan; in the brick-and-mortar pharmacy terminal, China Resources Sanjiu four exclusive products dominate the screen; in the online pharmacy terminal, the Taiji Group's exclusive oral liquid body agent for three consecutive years of soaring. In April this year, the Chinese medicine 1.1 new drug Xiangzhu Pingguxan was approved for clinical use, adding another member to the matrix of gastric Chinese medicine new drugs.

The market size of pCms gastric medicine (gastritis, ulcer) continued to decline in 2022-2023 at the terminals of China's urban public hospitals, county-level public hospitals, urban community centres and township health hospitals (referred to as China's public healthcare institutions), falling by 3.38% in 2023, with sales dropping to 7.03 billion yuan.

The leading group continues to be led by Yangzijiang Pharmaceuticals at a high level, with its market share remaining above 16% for three consecutive years, riding high. among the TOP10 groups in 2023, Handan Pharmaceuticals grew by 17.95%, with the group ranking rising to TOP5; Cubic Pharmaceuticals surged by 34%, with the group ranking jumping by four places and entering TOP6 for the first time.

Processed in 0.035544 Second , 30 querys.